Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dwyer

Showing results (251-260 of 260) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 260 results.
Bioorganic & Medicinal Chemistry Letters|August 29, 2016
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742Wensheng Yu, Guowei Zhou, Craig A Coburn, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2016
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742Wensheng Yu, Craig A Coburn, Anilkumar G Nair, et al.
Journal of Medicinal Chemistry|November 4, 2016
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated PolymorphismsLing Tong, Wensheng Yu, Lei Chen, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesKamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2016
Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR developmentAnilkumar G Nair, Qingbei Zeng, Oleg Selyutin, et al.
JAMA Network Open|October 5, 2023
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical TrialsPaul A Harris, Sarah E Dunsmore, Jane C Atkinson, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease InhibitorsChristopher J Bungard, Peter D Williams, Jurgen Schulz, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 23, 2017
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)Michael V Rocco, Kaycee M Sink, Laura C Lovato, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 26

Showing results (251-260 of 260) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 260 results.
Bioorganic & Medicinal Chemistry Letters|August 29, 2016
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742Wensheng Yu, Guowei Zhou, Craig A Coburn, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2016
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742Wensheng Yu, Craig A Coburn, Anilkumar G Nair, et al.
Journal of Medicinal Chemistry|November 4, 2016
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated PolymorphismsLing Tong, Wensheng Yu, Lei Chen, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesKamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2016
Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR developmentAnilkumar G Nair, Qingbei Zeng, Oleg Selyutin, et al.
JAMA Network Open|October 5, 2023
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical TrialsPaul A Harris, Sarah E Dunsmore, Jane C Atkinson, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease InhibitorsChristopher J Bungard, Peter D Williams, Jurgen Schulz, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 23, 2017
Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)Michael V Rocco, Kaycee M Sink, Laura C Lovato, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 31, 2020
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C Wheeler, Bergur V Stefansson, Mikhail Batiushin, et al.
Pageof 26